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Introduction
Pulmonary hypertension in end-stage renal failure is a 
newly recognized disorder and is accompanied by notably 
increased morbidity and mortality (1-3). The prevalence 
of pulmonary hypertension in subjects on hemodialysis 
is relatively high and varies in different studies from 
17% to 49.53% depending on the method of dialysis 
and other selection factors, such as the presence of other 
cardiovascular disease. Pulmonary hypertension is an 
independent predictor of mortality (3-6). There are various 
explanations including high cardiac output resulting 
from arteriovenous fistula (AVF), pulmonary artery 
calcifications, hypervolemia and anemia for pulmonary 
hypertension in patients with renal disease (5-8).
One of the prominent biochemical abnormalities in 
kidney failure is secondary hyperparathyroidism and 
increased parathormone. Parathyroid hormone (PTH) 
is found to enhance the entry of calcium into many 
cells, and chronic exposure to excess blood levels of 
parathormone is associated with increased calcium 
content of many tissues, hence it is, therefore, possible 
that the state of secondary hyperparathyroidism is one of 
the factors responsible for the pulmonary hypertension in 
hemodialysis patients (9-12).
Objectives
Therefore, this study was aimed to examine, the possible 
association of serum PTH level with pulmonary artery 
pressure in a group of non-diabetic hemodialysis patients 
on regular hemodialysis. 
Materials and Methods
This prospective study was conducted in the hemodialysis 
unit of Shahrekord University of Medical Sciences. 
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The patients’ data containing age, gender, medications, 
tobacco use, vascular access type, etiology of renal failure 
and duration of hemodialysis were recorded. All enrolled 
patients were on hemodialysis three times a week for four 
hours using polysulfone membranes, reverse osmosis 
purified water, bicarbonate-base hemodialysis solution 
and low-flux dialysis filters. The inclusion criterion was 
presence of AVF. The exclusion criteria were cigarette 
smoking, cardiac disease, presence of pericarditis or 
pericardial effusion, presence of any respiratory illness 
or pulmonary infection and use of calcium channel 
blockers medications. Furthermore, patients treated 
with hemodialysis below one year was not included 
in this investigation. Also patients with the history of 
collagen vascular disease, volume overload at the time of 
echocardiography (<50% collapsibility in IVC diameter) 
and positive human immunodeficiency virus (HIV) test 
were excluded from the study.
 
Pulmonary artery measuring
Echocardiography was conducted for all of the patients. 
Doppler echocardiography was used to evaluate left 
ventricular ejection fraction and to establish the 
pulmonary artery pressure, expiratory and inspiratory 
inferior vena cava (IVC) diameters, presence of pericarditis 
or pericardial effusion and presence of valvular disease. 
Pulmonary arterial hypertension is characterized as 
systolic PAP≥35 mm Hg at rest (4,13).
Laboratory assessments
Blood samples were obtained after a long dialysis-free 
weekend interval before the next hemodialysis, after a 
minimum 8-hour overnight fast to avoid the circadian 
and feeding impact on serum adiponectin fluctuations. 
Serum intact parathormone (iPTH) was measured by ECL 
method (reference range; 10.9-54.8 ρg/ml).
Ethical issues
1) The research followed the tenets of the Declaration 
of Helsinki and Good Clinical Practice guidelines; 2) 
informed consent was obtained; and 3) the research was 
approved by ethical committee of Shahrekord University 
of Medical Sciences.
 Implication for health policy/practice/research/
medical education
In the present study, we detected a significant positive 
association of serum PTH with pulmonary artery 
pressure of hemodialysis patients however, our 
observations, warranting further investigations to 
evaluate the clinical aspect of the association of serum 
PTH with pulmonary artery pressure.
Statistical analysis
Values are expressed as mean (±SD). All analysis were 
performed using the procedure of SAS version 9.2 
(SAS Inc., Cary, NC, USA). Difference in mean serum 
adiponectin and pulmonary artery pressure between 
male and female was evaluated by paired Student’s t-test. 
The strength of the association between the variables was 
estimated by Pearson’s correlation coefficient. A p-value 
less than 0.05 was considered significant.
Results
Sixty-five, non-diabetic hemodialysis patients were 
studied. Mean (±SD) of age of the patients was 56.35±20.41 
years. Mean (±SD) of iPTH was 251.55±97.27 ρg/ml 
(Minimum: 85; maximum: 525 ρg/ml). The length of the 
time hemodialysis patients on dialysis was 5.06 (±5.04) 
years. The value of pulmonary artery pressure was 32.32 
(±20.67) mm Hg. In this study, a significant positive 
association of serum iPTH with pulmonary artery 
pressure in patients was seen (r=0.27, p=0.029; Figure 1).
Discussion
In this study, we detected a significant positive association 
of serum iPTH with pulmonary artery pressure of 
hemodialysis patients. Pulmonary arterial hypertension 
is not uncommon illness in patient under hemodialysis 
through arteriovenous access (1-8). The etiology of 
pulmonary hypertension is not fully understood, while 
various factors interacted. It is hypothesized that, 
arteriovenous fistula-induced increased cardiac output, 
and accordingly increment of pulmonary artery pressure. 
Other factors except AVF are anemia and hypervolemia 
(2-7). It is also possible that micro-bubbles escaping from 
the hemodialysis circuit can cause vasoconstriction and 
vascular sclerosis (4-8). Various investigations had detected 
that, pulmonary vessels show signs of dysregulation 
of vascular tone and endothelial dysfunction due to 
an imbalance in vasoactive substances, and local and 
systemic micro-inflammation (1-4). Previously in a study 
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Figure 1. Significant positive association of serum iPTH with 
pulmonary artery pressure
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on 102 regular hemodialysis patients, Nasri et al., detected 
a pulmonary artery pressure of 41.5 ± 12.6 mm Hg. They 
found, 76.5% of hemodialysis patients had pulmonary 
artery pressure ≥ 35 mm Hg (13). They also found that 
pulmonary artery pressure had significant positive 
association with the duration and degree of hemodialysis. 
Kumbar et al. tested the prevalence and characteristics of 
pulmonary hypertension in peritoneal dialysis patients. 
They observed a pulmonary hypertension of 42% in their 
study patients. They detected, the values of pulmonary 
artery pressure correlated directly with serum levels of 
phosphorus, Ca×P product, and also level of PTH (7). It 
is possible that pulmonary artery calcifications secondary 
to hyperparathyroidism, responsible for pulmonary 
hypertension in dialysis patients (3-8). Previously, Nasri 
et al., also had shown the positive association of serum 
intact parathormone and pulmonary hypertension 
in hemodialysis patients (14), a finding which was 
demonstrated by others too (15) and was also conformed
with the result of our study. However, it is unclear the 
exact role PTH in pulmonary hypertension and needs 
further investigation. 
Conclusion
In the present study, we detected a significant positive 
association of serum PTH with pulmonary artery pressure 
of hemodialysis patients however, our observations, 
warranting further investigations to evaluate the clinical 
aspect of the association of serum PTH with pulmonary 
artery pressure.
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